STRUCTURE THERAPEUTICS INC. AMERICAN DEPOSITARY SHARES

NASDAQ: GPCR (Structure Therapeutics Inc.)

Kemas kini terakhir: 19 jam lalu

16.13

-0.99 (-5.78%)

Penutupan Terdahulu 17.12
Jumlah Dagangan 786,235
Purata Dagangan (3B) 1,176,959
Modal Pasaran 1,154,752,256
Harga / Buku (P/B) 1.01
Julat 52 Minggu
16.06 (-0%) — 94.90 (488%)
Tarikh Pendapatan 9 Nov 2026
EPS Cair (TTM) -3.90
Jumlah Hutang/Ekuiti (D/E MRQ) 0.56%
Nisbah Semasa (MRQ) 11.90
Aliran Tunai Operasi (OCF TTM) -271.00 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -148.98 M
Pulangan Atas Aset (ROA TTM) -20.23%
Pulangan Atas Ekuiti (ROE TTM) -29.51%

AISkor Stockmoo

-0.7
Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info
Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga telah jatuh jauh di bawah purata itu. Dagangan lebih tinggi pada hari harga turun. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini bercampur atau neutral. info
Sentimen Pegangan info NA
Institusi bersih +5.81% daripada saham dalam pemfailan 13F terkini: 78 pemegang menambah, 112 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat +1.2% dari 31 Aug hingga 30 Oct 2026, 6.5 hari untuk tutup (FINRA). info
Aktiviti Orang Dalam info NA
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak tidak sependapat, jadi skor dilemahkan.
Perolehan sesaham kebanyakannya menurun. Mencatat kerugian dalam tahun-tahun kebelakangan. info
Di bawah garis aliran jangka sederhana. info
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Momentum jangka pendek menurun. info
Paras sokongan dan rintangan menaik. info
Skor Akhir -0.72
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Structure Therapeutics Inc. Bercampur Menaik

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
GPCR 1 B - - 1.01 -0.7
PBLS 3 B - - 3.38 0.8
LEGN 3 B - - 2.59 -1.6
PVLA 2 B - - 10.82 0.9
MAZE 2 B - - 4.13 0.9
IMCR 1 B - - 3.24 -0.2

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 3.10%
% Dimiliki oleh Institusi 97.79%

Pemilikan

Nama Tarikh Syer Dipegang
Avoro Capital Advisors Llc 30 Sep 2026 6,555,555

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 34.48%

Kedudukan Pemegang Saham
Bertambah 78 16,027,429
Berkurang 112 9,944,170
Baharu 28 8,724,695
Dijual habis 46 2,322,694

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 5,927,622 6.5
15 Oct 2026 7,147,328 4.8
30 Sep 2026 7,540,480 5.2
15 Sep 2026 6,605,011 5.2
31 Aug 2026 5,854,907 7.9
14 Aug 2026 6,079,970 10.4

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

1 Positif 1 Negatif 3 Neutral
Tarikh Jenis Butiran
16 Nov 2026 Yahoo Finance Structure Therapeutics (GPCR) Posts Wider Losses, Is The Discount Too Deep?
Structure Therapeutics (GPCR) put its third quarter in focus for investors after reporting a wider net loss of US$144.76 million and a higher loss per share, with year-to-date figures showing a similar pattern. Structure Therapeutics’ share price has fallen sharply over 2026, with a year to date…
13 Nov 2026 Yahoo Finance 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
12 Nov 2026 Yahoo Finance Unlearn and Structure Therapeutics Collaborate to Apply AI-Generated Digital Twins in Obesity Research
Retrospective analysis at ObesityWeek® will explore how AI-based modeling can provide context for longer-term obesity study resultsSAN FRANCISCO, CA / ACCESS Newswire / November 12, 2026 / Unlearn today announced a collaboration with Structure Therapeutics Inc., a clinical-stage biopharmaceutical…
09 Nov 2026 Yahoo Finance Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 Additional aleniglipron data expected in Q4 2026 from supplementary body composition, type 2 diabetes and SWITCH studies…
04 Nov 2026 Yahoo Finance Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced that management will…
27 Oct 2026 Yahoo Finance Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 Earnings
Lilly heads into Q3 earnings with Mounjaro, Zepbound and new drugs fueling growth, but pricing pressure, rising costs and competition pose challenges.
21 Oct 2026 Yahoo Finance How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.
19 Oct 2026 Yahoo Finance Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming…
19 Oct 2026 Yahoo Finance How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
LLY's surging Mounjaro and Zepbound sales, alongside Foundayo's expanding market access, strengthen its GLP-1 growth momentum ahead of Q3 results.
16 Oct 2026 Yahoo Finance Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base
Structure Therapeutics has seen a sharp reset in market sentiment this year, which puts fresh focus on whether the current share price lines up with what its balance sheet can support. With the stock under pressure, the central question is how that drop squares with its book value. Year to date…
12 Oct 2026 Yahoo Finance Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
08 Oct 2026 Yahoo Finance LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
LLY's recent dip reflects valuation and competition concerns, but strong GLP-1 demand, pipeline growth and diversification support its long-term outlook.
30 Sep 2026 Yahoo Finance Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
23 Sep 2026 Yahoo Finance Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1…
22 Sep 2026 Yahoo Finance Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.
22 Sep 2026 Yahoo Finance Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus
Structure Therapeutics (GPCR) has put fresh clinical data for its oral obesity pipeline in front of investors, highlighting results from early stage ACCG-2671 studies and longer term aleniglipron weight loss trials. Recent trading tells a mixed story for Structure Therapeutics. The 1-day share…
22 Sep 2026 Yahoo Finance VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.
Papar semua

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan –
Dagangan
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga telah jatuh jauh di bawah purata itu. Dagangan lebih tinggi pada hari harga turun.
Rintangan terdekat: 18.35 – 19.05 · paras sederhana

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Risiko / Ganjaran
TP1:
TP2:

Kerugian hingga SL berbanding keuntungan hingga setiap sasaran, dari EP. Nisbah 2 atau lebih biasanya dicari.

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda